


PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Collection of information unless it contains a valid OMB control number.



Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Attorney Docket Number

FRAV2003/0005 - US - NP

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

FRANK
LANGUAGE
DOCUMENT

**Examiner
Signature**

Louis Wollenberger

Date
Considered

8/31/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/774,721	
			Filing Date	02-09-2004	
			First Named Inventor	JOCKERS, et al.	
			Group Art Unit	Not Yet Known	
			Examiner Name	Not Yet Known	
Sheet	2	of	2	Attorney Docket Number	FRAV2003/0005 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
fw		A. LUNDIN et al., Expression and intracellular localization of leptin receptor long isoform-GFP chimera, Biochimica et Biophysica Acta, Vol. 1499, No. 1-2, pp. 130-138	
fw		B. BAILLEUL et al., The leptin receptor promoter controls expression of a second distinct protein, Nucleic Acids Research, Vol. 25, No. 14, July 15, 1997, pp. 2752-2758	
fw		K. SERON et al., OB-RGRP and Leprotl1 Define a New Family of Lipid Raft-Associated Tetraspanning Membrane Proteins Localized At the TGN and/or Endosomes, Biology of the Cell, Vol. 93, No. 3/4, Nov. 7, 2001, page 227	
fw		L. TARTAGLIA et al., Identification and Expression Cloning of a Leptin Receptor, OB-R, Cell, Vol. 83, No. 7, Dec. 29, 1995, pp. 1263-1271	
fw		N. BOUTE et al., Monitoring the Activation State of the Insulin Receptor Using Bioluminescence Resonance Energy Transfer, Molecular Pharmacology, Vol. 60, No. 4, Oct. 2001, pp. 640-645	
fw		N. BOUTE et al., The use of resonance energy transfer in high-throughput screening: BRET versus FRET, Trends in Pharmacological Sciences, Vol. 213, No. 8, August 2002, pp. 351-354	
fw		T. EFFERTH, Leptin contributes to the protection of human leukemic cells from cisplatinum cytotoxicity, Anticancer Research, Vol. 20, No. 4, July 2000, pp. 2541-2546	
fw		Y. HUANG et al., Cloning and characterization of a novel leptin receptor overlapping transcript-like 1 gene (LEPROTL1), Biochimica et Biophysica Acta, Vol. 1517, No. 2, Jan. 26, 2001, pp. 327-331	

Examiner Signature	<i>Louis Wollenberg</i>	Date Considered	8/31/05
--------------------	-------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.